Eiji Ikeda
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Eiji Ikeda has a total of 153 co-authors. Here are the top co-authors by number of shared publications:
Dan Cui
Departments of Pathology, Yamaguchi University Graduate School of Medicine, 1-1-1 Minami-Kogushi, Ube, Yamaguchi 755-8505, Japan
7 shared publications- Aya Ishii
Department of Anatomic Pathology, Kurashiki Central Hospital, Okayama, Japan
5 shared publications Hiroo Kawano
Department of Basic Laboratory Sciences, Yamaguchi University Graduate School of Medicine, Ube, Japan
5 shared publicationsTokuhiro Kimura
Department of Pathology, Yamaguchi University Graduate School of Medicine, Ube, Japan
5 shared publicationsMitsuru Arima
Department of Pathology, Yamaguchi University Graduate School of Medicine, 1-1-1 Minami-Kogushi, Ube, Yamaguchi, 755-8505, Japan; Department of Ophthalmology, Kyushu University Graduate School of Medical Sciences, 3-1-1 Maidashi, Higashi-ku, Fukuoka City, Fukuoka, 812-8582, Japan
3 shared publicationsSatoshi Matsuda
Department of Cell Signaling, Institute of Biomedical Sciences, Kansai Medical University, Hirakata, Japan
3 shared publications
Latest Publications
- Open Access
- 1 January 2026
- Published by S. Karger AG in Case Reports in Oncology
- Vol. 19 (1) , 293-301
Epstein-Barr Virus-Positive Inflammatory Follicular Dendritic Cell Sarcoma Occurring in Spleen of a Patient after Chemotherapy for Lung Carcinoma: A Case Report
Introduction: Epstein-Barr virus (EBV)-positive inflammatory follicular dendritic cell sarcoma (EBV+ inflammatory FDCS) is a rare neoplasm that occurs almost exclusively in the spleen and liver. Although EBV+ inflammatory FDCS is recognized to show indolent behavior, its pathophysiology including the pathogenesis remains unclear. Case Presentation: We present an EBV+ inflammatory FDCS, which occurred in the spleen of a patient under the follow-up for chemotherapy against lung carcinoma. Sequential CT examinations reveal that a splenic lesion was first detectable 5 years after chemotherapy and has grown for another 3 years to form a mass of 4 cm in diameter. Splenectomy was performed. Histologically, a well-circumscribed lesion in the spleen exhibited the significant infiltration of lymphocytes and plasma cells in the background of hyalinized fibrous tissue, and large oval-shaped cells were intermingled with lymphocytes and plasma cells. Large oval-shaped cells were found to express CD21 and CD23, and they were shown to be positive for EBV-encoded small RNA in situ hybridization. Based on these findings, the splenic lesion was diagnosed as EBV+ inflammatory FDCS. Conclusion: The present case might provide information to discuss the possible pathogenesis of EBV+ inflammatory FDCS in the context of immunosuppression.
- 1 January 2026
- Published by S. Karger AG in Case Reports in Oncology
- Vol. 19 (1) , 293-301
Open AccessEpstein-Barr Virus-Positive Inflammatory Follicular Dendritic Cell Sarcoma Occurring in Spleen of a Patient after Chemotherapy for Lung Carcinoma: A Case Report
Introduction: Epstein-Barr virus (EBV)-positive inflammatory follicular dendritic cell sarcoma (EBV+ inflammatory FDCS) is a rare neoplasm that occurs almost exclusively in the spleen and liver. Although EBV+ inflammatory FDCS is recognized to show indolent behavior, its pathophysiology including the pathogenesis remains unclear. Case Presentation: We present an EBV+ inflammatory FDCS, which occurred in the spleen of a patient under the follow-up for chemotherapy against lung carcinoma. Sequential CT examinations reveal that a splenic lesion was first detectable 5 years after chemotherapy and has grown for another 3 years to form a mass of 4 cm in diameter. Splenectomy was performed. Histologically, a well-circumscribed lesion in the spleen exhibited the significant infiltration of lymphocytes and plasma cells in the background of hyalinized fibrous tissue, and large oval-shaped cells were intermingled with lymphocytes and plasma cells. Large oval-shaped cells were found to express CD21 and CD23, and they were shown to be positive for EBV-encoded small RNA in situ hybridization. Based on these findings, the splenic lesion was diagnosed as EBV+ inflammatory FDCS. Conclusion: The present case might provide information to discuss the possible pathogenesis of EBV+ inflammatory FDCS in the context of immunosuppression.
- 24 September 2024
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 120 (1) , 23
Epstein-Barr Virus-Associated Colitis With Infectious Mononucleosis
An abstract is unavailable. This article is available as a PDF only.
- 24 September 2024
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 120 (1) , 23
Epstein-Barr Virus-Associated Colitis With Infectious Mononucleosis
An abstract is unavailable. This article is available as a PDF only.
- Open Access
- 10 July 2024
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-11
Characterizing soluble immune checkpoint molecules and TGF-β1,2,3 in pleural effusion of malignant pleural mesothelioma
The clinical impact of soluble molecules in pleural effusion (PE) is unclear in patients with malignant pleural mesothelioma (MPM). In this single-center, retrospective, observational study, we assessed soluble forms of cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), programmed cell death protein 1 (PD-1), and PD-1 ligand 1 (PD-L1) using enzyme-linked immunosorbent assays; three TGF-β isoforms were measured via multiplex assay in PE of patients with fibrinous pleuritis (FP) or MPM, to assess relationships between the levels of six molecules, clinicopathological characteristics, and efficacy of immune checkpoint inhibitors. Soluble forms of CTLA-4, PD-L1, PD-1, TGF-β1, TGF-β2, and TGF-β3 were variably produced in PE of FP (n = 34) and MPM (n = 79); we found significant relationships between the six molecules and clinicopathological features. Although none of the three soluble immune checkpoint molecules showed diagnostic or prognostic effects in patients with MPM, TGF-β2 level in PE is a useful differential diagnostic marker between FP and MPM. Both TGF-β1 and TGF-β3 levels are promising prognostic markers for MPM. Moreover, we found that higher baseline levels of PD-1 soluble forms predicted the response to anti-PD1 monotherapy. Our findings identify novel diagnostic, prognostic, and predictive biomarkers for anti-PD1 therapy in patients with MPM.
- 10 July 2024
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-11
Open AccessCharacterizing soluble immune checkpoint molecules and TGF-β1,2,3 in pleural effusion of malignant pleural mesothelioma
The clinical impact of soluble molecules in pleural effusion (PE) is unclear in patients with malignant pleural mesothelioma (MPM). In this single-center, retrospective, observational study, we assessed soluble forms of cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), programmed cell death protein 1 (PD-1), and PD-1 ligand 1 (PD-L1) using enzyme-linked immunosorbent assays; three TGF-β isoforms were measured via multiplex assay in PE of patients with fibrinous pleuritis (FP) or MPM, to assess relationships between the levels of six molecules, clinicopathological characteristics, and efficacy of immune checkpoint inhibitors. Soluble forms of CTLA-4, PD-L1, PD-1, TGF-β1, TGF-β2, and TGF-β3 were variably produced in PE of FP (n = 34) and MPM (n = 79); we found significant relationships between the six molecules and clinicopathological features. Although none of the three soluble immune checkpoint molecules showed diagnostic or prognostic effects in patients with MPM, TGF-β2 level in PE is a useful differential diagnostic marker between FP and MPM. Both TGF-β1 and TGF-β3 levels are promising prognostic markers for MPM. Moreover, we found that higher baseline levels of PD-1 soluble forms predicted the response to anti-PD1 monotherapy. Our findings identify novel diagnostic, prognostic, and predictive biomarkers for anti-PD1 therapy in patients with MPM.
- Open Access
- 22 December 2023
- Published by Wiley in Thoracic Cancer
- Vol. 15 (4) , 353-357
A case of primary lung adenocarcinoma mimicking metastatic papillary thyroid carcinoma
A 61-year-old woman, who had a history of total thyroidectomy for follicular variant of papillary thyroid carcinoma (PTC), visited our hospital for assessment of an enlarging nodule which appeared in the lung with multiple metastatic lesions of PTC which had been stable for 17 years. Wedge resection of the lung was performed. Miliary nodules were confirmed to be metastatic PTCs based on their morphological as well as immunohistochemical findings. As for the main nodule, its morphological features suggested a diagnosis of metastatic PTC, while its immunohistochemical findings were identical with primary lung adenocarcinoma. Further genetic analysis provided no definitive information for the diagnosis of the main nodule. The present case shows the need of comprehensive analyses for differentiation between primary lung adenocarcinoma and metastatic PTCs. We report a case of primary lung adenocarcinoma arising in the lung with multiple metastatic nodules of the follicular variant of papillary thyroid carcinoma (PTC). This case highlights the need for comprehensive analyses including morphology, immunohistochemistry and genetic analyses to differentiate the primary lung adenocarcinoma from the metastatic PTCs.image
- 22 December 2023
- Published by Wiley in Thoracic Cancer
- Vol. 15 (4) , 353-357
Open AccessA case of primary lung adenocarcinoma mimicking metastatic papillary thyroid carcinoma
A 61-year-old woman, who had a history of total thyroidectomy for follicular variant of papillary thyroid carcinoma (PTC), visited our hospital for assessment of an enlarging nodule which appeared in the lung with multiple metastatic lesions of PTC which had been stable for 17 years. Wedge resection of the lung was performed. Miliary nodules were confirmed to be metastatic PTCs based on their morphological as well as immunohistochemical findings. As for the main nodule, its morphological features suggested a diagnosis of metastatic PTC, while its immunohistochemical findings were identical with primary lung adenocarcinoma. Further genetic analysis provided no definitive information for the diagnosis of the main nodule. The present case shows the need of comprehensive analyses for differentiation between primary lung adenocarcinoma and metastatic PTCs. We report a case of primary lung adenocarcinoma arising in the lung with multiple metastatic nodules of the follicular variant of papillary thyroid carcinoma (PTC). This case highlights the need for comprehensive analyses including morphology, immunohistochemistry and genetic analyses to differentiate the primary lung adenocarcinoma from the metastatic PTCs.image
- Open Access
- 29 November 2023
- Published by Elsevier in The American Journal of Pathology
- Vol. 194 (4) , 612-625
High-Mannose–Type Glycan of Basigin in Endothelial Cells Is Essential for the Opening of the Blood–Brain Barrier Induced by Hypoxia, Cyclophilin A, or Tumor Necrosis Factor-α
- 29 November 2023
- Published by Elsevier in The American Journal of Pathology
- Vol. 194 (4) , 612-625
Open AccessHigh-Mannose–Type Glycan of Basigin in Endothelial Cells Is Essential for the Opening of the Blood–Brain Barrier Induced by Hypoxia, Cyclophilin A, or Tumor Necrosis Factor-α
- Open Access
- 16 May 2023
- Published by Elsevier in Respiratory Medicine Case Reports
- Vol. 44, 101862
A case of development of autoimmune pulmonary alveolar proteinosis during the treatment of hypersensitivity pneumonitis
- 16 May 2023
- Published by Elsevier in Respiratory Medicine Case Reports
- Vol. 44, 101862
Open AccessA case of development of autoimmune pulmonary alveolar proteinosis during the treatment of hypersensitivity pneumonitis
- Open Access
- 29 September 2021
- Published by Springer Nature in Scientific Reports
- Vol. 11 (1) , 1-9
Intravenous injection of cyclophilin A realizes the transient and reversible opening of barrier of neural vasculature through basigin in endothelial cells
Neural vasculature forms the blood–brain barrier against the delivery of systemically administered therapeutic drugs into parenchyma of neural tissues. Therefore, procedures to open the blood–brain barrier with minimal damage to tissues would lead to the great progress in therapeutic strategy for intractable neural diseases. In this study, through analyses with mouse in vitro brain microvascular endothelial cells and in vivo neural vasculature, we demonstrate that the administration of cyclophilin A (CypA), a ligand of basigin which is expressed in barrier-forming endothelial cells, realizes the artificial opening of blood–brain barrier. Monolayers of endothelial cells lost their barrier properties through the disappearance of claudin-5, an integral tight junction molecule, from cell membranes in a transient and reversible manner. Furthermore, the intravenous injection of a single dose of CypA into mice resulted in the opening of blood–brain barrier for a certain period which enabled the enhanced delivery of systemically administered doxorubicin into the parenchyma of neural tissues. These findings that the pre-injection of a single dose of CypA realizes an artificial, transient as well as reversible opening of blood–brain barrier are considered to be a great step toward the establishment of therapeutic protocols to overcome the intractability of neural diseases.
- 29 September 2021
- Published by Springer Nature in Scientific Reports
- Vol. 11 (1) , 1-9
Open AccessIntravenous injection of cyclophilin A realizes the transient and reversible opening of barrier of neural vasculature through basigin in endothelial cells
Neural vasculature forms the blood–brain barrier against the delivery of systemically administered therapeutic drugs into parenchyma of neural tissues. Therefore, procedures to open the blood–brain barrier with minimal damage to tissues would lead to the great progress in therapeutic strategy for intractable neural diseases. In this study, through analyses with mouse in vitro brain microvascular endothelial cells and in vivo neural vasculature, we demonstrate that the administration of cyclophilin A (CypA), a ligand of basigin which is expressed in barrier-forming endothelial cells, realizes the artificial opening of blood–brain barrier. Monolayers of endothelial cells lost their barrier properties through the disappearance of claudin-5, an integral tight junction molecule, from cell membranes in a transient and reversible manner. Furthermore, the intravenous injection of a single dose of CypA into mice resulted in the opening of blood–brain barrier for a certain period which enabled the enhanced delivery of systemically administered doxorubicin into the parenchyma of neural tissues. These findings that the pre-injection of a single dose of CypA realizes an artificial, transient as well as reversible opening of blood–brain barrier are considered to be a great step toward the establishment of therapeutic protocols to overcome the intractability of neural diseases.
- Open Access
- 11 January 2021
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 6 (1)
Islet cell dedifferentiation is a pathologic mechanism of long-standing progression of type 2 diabetes
Dedifferentiation has been implicated in β cell dysfunction and loss in rodent diabetes. However, the pathophysiological significance in humans remains unclear. To elucidate this, we analyzed surgically resected pancreatic tissues of 26 Japanese subjects with diabetes and 11 nondiabetic subjects, who had been overweight during adulthood but had no family history of diabetes. The diabetic subjects were subclassified into 3 disease stage categories, early, advanced, and intermediate. Despite no numerical changes in endocrine cells immunoreactive for chromogranin A (ChgA), diabetic islets showed profound β cell loss, with an increase in α cells without an increase in insulin and glucagon double-positive cells. The proportion of dedifferentiated cells that retain ChgA immunoreactivity without 4 major islet hormones was strikingly increased in diabetic islets and rose substantially during disease progression. The increased dedifferentiated cell ratio was inversely correlated with declining C-peptide index. Moreover, a subset of islet cells converted into exocrine-like cells during disease progression. These results indicate that islet remodeling with dedifferentiation is the underlying cause of β cell failure during the course of diabetes progression in humans.
- 11 January 2021
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 6 (1)
Open AccessIslet cell dedifferentiation is a pathologic mechanism of long-standing progression of type 2 diabetes
Dedifferentiation has been implicated in β cell dysfunction and loss in rodent diabetes. However, the pathophysiological significance in humans remains unclear. To elucidate this, we analyzed surgically resected pancreatic tissues of 26 Japanese subjects with diabetes and 11 nondiabetic subjects, who had been overweight during adulthood but had no family history of diabetes. The diabetic subjects were subclassified into 3 disease stage categories, early, advanced, and intermediate. Despite no numerical changes in endocrine cells immunoreactive for chromogranin A (ChgA), diabetic islets showed profound β cell loss, with an increase in α cells without an increase in insulin and glucagon double-positive cells. The proportion of dedifferentiated cells that retain ChgA immunoreactivity without 4 major islet hormones was strikingly increased in diabetic islets and rose substantially during disease progression. The increased dedifferentiated cell ratio was inversely correlated with declining C-peptide index. Moreover, a subset of islet cells converted into exocrine-like cells during disease progression. These results indicate that islet remodeling with dedifferentiation is the underlying cause of β cell failure during the course of diabetes progression in humans.
- Open Access
- 1 August 2020
- Published by Elsevier in Trauma & Case Reports
- Vol. 28, 100319
Diagnostic and therapeutic role of endoscopic retrograde pancreatography and stent placement for grade IV blunt pancreatic trauma: A case report
- 1 August 2020
- Published by Elsevier in Trauma & Case Reports
- Vol. 28, 100319
Open AccessDiagnostic and therapeutic role of endoscopic retrograde pancreatography and stent placement for grade IV blunt pancreatic trauma: A case report
- Open Access
- 1 June 2019
- Published by Elsevier in Experimental Cell Research
- Vol. 379 (2) , 166-171
Hypoxia-induced disruption of neural vascular barrier is mediated by the intracellular induction of Fe(II) ion
- 1 June 2019
- Published by Elsevier in Experimental Cell Research
- Vol. 379 (2) , 166-171
Open AccessHypoxia-induced disruption of neural vascular barrier is mediated by the intracellular induction of Fe(II) ion